当前位置: X-MOL 学术Nat. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Perioperative immunotherapy for bladder cancer
Nature Medicine ( IF 58.7 ) Pub Date : 2024-10-16 , DOI: 10.1038/d41591-024-00074-6


In the NIAGARA trial, the addition of perioperative durvalumab to standard treatment for muscle-invasive bladder cancer improved event-free and overall survival, marking a new treatment option for this condition.

中文翻译:


膀胱癌的围手术期免疫治疗



在 NIAGARA 试验中,在肌层浸润性膀胱癌的标准治疗中加入围手术期 durvalumab 提高了无事件生存期和总生存期,标志着这种情况的新治疗选择。
更新日期:2024-10-17
down
wechat
bug